<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858896</url>
  </required_header>
  <id_info>
    <org_study_id>HP00055308</org_study_id>
    <nct_id>NCT01858896</nct_id>
  </id_info>
  <brief_title>GLP-1 and Hypoglycemia</brief_title>
  <official_title>Hypoglycemia Associated Autonomic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low blood sugar can negatively affect how blood vessels function, and this can lead to an
      increase in the risk for heart attacks, strokes and other problems related to the stiffening
      and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like
      peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low
      blood sugar levels have on blood vessels.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasminogen Activation inhibitor-1 (PAi-1)</measure>
    <time_frame>change from baseline to end of clamp period</time_frame>
    <description>measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Flow mediated dilation (FMD)</measure>
    <time_frame>change from baseline and end of clamp</time_frame>
    <description>flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (~4 hours)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glucagon-Like Peptide -1 (GLP-1) infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of GLP-1 during experimental period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion during experimental period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-Like Peptide- 1 (GLP-1) infusion</intervention_name>
    <description>GLP-1 infusion during experimental period</description>
    <arm_group_label>Glucagon-Like Peptide -1 (GLP-1) infusion</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: Saline Infusion</intervention_name>
    <description>Saline infusion (placebo) during experimental period</description>
    <arm_group_label>Saline Infusion</arm_group_label>
    <other_name>Saline infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14 (7 males, 7 females) healthy controls age 30-60 yr.

          -  14 (7 males, 7 females) people with type 2 DM age 30-60 yr.

          -  For type 2 DM: HbA1c 6-10.0%

          -  No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy,
             stasis ulcers, etc.)

          -  Body mass index &gt;25kg â€¢ m-2

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N Davis, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis, MBBS</investigator_full_name>
    <investigator_title>Chairman of Medicine</investigator_title>
  </responsible_party>
  <keyword>hypoglycemia</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

